Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Playing the melanoma endgame.

Teh JLF, Aplin AE.

Clin Cancer Res. 2018 May 16. pii: clincanres.0989.2018. doi: 10.1158/1078-0432.CCR-18-0989. [Epub ahead of print]

PMID:
29769205
2.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.

3.

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.

Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y.

Nat Commun. 2018 Apr 6;9(1):1404. doi: 10.1038/s41467-018-03710-1.

4.

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.

Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN.

Cancer Discov. 2018 May;8(5):556-567. doi: 10.1158/2159-8290.CD-17-0745. Epub 2018 Mar 1.

PMID:
29496665
5.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1.

PMID:
29496664
6.

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma.

Han S, Ren Y, He W, Liu H, Zhi Z, Zhu X, Yang T, Rong Y, Ma B, Purwin TJ, Ouyang Z, Li C, Wang X, Wang X, Yang H, Zheng Y, Aplin AE, Liu J, Shao Y.

Nat Commun. 2018 Jan 2;9(1):28. doi: 10.1038/s41467-017-02354-x. Erratum in: Nat Commun. 2018 Apr 6;9(1):1404.

7.

Novel therapeutic strategies and targets in advanced uveal melanoma.

Chua V, Aplin AE.

Curr Opin Oncol. 2018 Mar;30(2):134-141. doi: 10.1097/CCO.0000000000000425.

PMID:
29206651
8.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

9.

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.

Hartsough EJ, Kugel CH 3rd, Vido MJ, Berger AC, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE.

Mol Cancer Ther. 2018 Jan;17(1):84-95. doi: 10.1158/1535-7163.MCT-17-0705. Epub 2017 Nov 13.

PMID:
29133617
10.

"If you want to go far, go together".

Aplin AE.

Pigment Cell Melanoma Res. 2017 Sep;30(5):448. doi: 10.1111/pcmr.12619. No abstract available.

PMID:
28834183
11.

Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.

Kageyama K, Ohara M, Saito K, Ozaki S, Terai M, Mastrangelo MJ, Fortina P, Aplin AE, Sato T.

J Transl Med. 2017 Jun 23;15(1):145. doi: 10.1186/s12967-017-1247-z.

12.

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, Alicea GM, Wang J, Ghosh K, Cheng P, Lisanti S, Marchbank K, Dang V, Levesque M, Dummer R, Xu X, Herlyn M, Aplin AE, Roesch A, Caino C, Altieri DC, Weeraratna AT.

Clin Cancer Res. 2017 Jun 15;23(12):3181-3190. doi: 10.1158/1078-0432.CCR-17-0201. Epub 2017 Feb 23.

13.

Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.

Chua V, Lapadula D, Randolph C, Benovic JL, Wedegaertner PB, Aplin AE.

Mol Cancer Res. 2017 May;15(5):501-506. doi: 10.1158/1541-7786.MCR-17-0007. Epub 2017 Feb 21. Review.

14.

Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Chua V, Liao C, Purwin TJ, Terai M, Kageyama K, Davies MA, Sato T, Aplin AE.

Mol Cancer Ther. 2017 Mar;16(3):516-528. doi: 10.1158/1535-7163.MCT-16-0552. Epub 2017 Jan 30.

15.

An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma.

Teh JL, Purwin TJ, Greenawalt EJ, Chervoneva I, Goldberg A, Davies MA, Aplin AE.

Cancer Res. 2016 Sep 15;76(18):5455-66. doi: 10.1158/0008-5472.CAN-15-3384. Epub 2016 Aug 3.

16.

The melanoma field with dendritic roots.

Aplin AE.

Pigment Cell Melanoma Res. 2016 Jul;29(4):397. doi: 10.1111/pcmr.12496. No abstract available.

PMID:
27320440
17.

The state of melanoma: challenges and opportunities.

Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA.

Pigment Cell Melanoma Res. 2016 Jul;29(4):404-16. doi: 10.1111/pcmr.12475. Epub 2016 Apr 17.

18.

Targeting mutant NRAS signaling pathways in melanoma.

Vu HL, Aplin AE.

Pharmacol Res. 2016 May;107:111-116. doi: 10.1016/j.phrs.2016.03.007. Epub 2016 Mar 15. Review.

19.

MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.

Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, Berger AC, Aplin AE.

J Invest Dermatol. 2016 Feb;136(2):453-63. doi: 10.1016/j.jid.2015.11.012. Epub 2015 Nov 20.

20.

Of Mice and Melanoma: PDX System for Modeling Personalized Medicine.

Hartsough EJ, Aplin AE.

Clin Cancer Res. 2016 Apr 1;22(7):1550-2. doi: 10.1158/1078-0432.CCR-15-3054. Epub 2016 Feb 3.

21.

Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization.

Ozaki S, Vuyyuru R, Kageyama K, Terai M, Ohara M, Cheng H, Manser T, Mastrangelo MJ, Aplin AE, Sato T.

Am J Pathol. 2016 Jan;186(1):43-56. doi: 10.1016/j.ajpath.2015.09.011. Epub 2015 Nov 25.

22.

Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer.

Talati PG, Gu L, Ellsworth EM, Girondo MA, Trerotola M, Hoang DT, Leiby B, Dagvadorj A, McCue PA, Lallas CD, Trabulsi EJ, Gomella L, Aplin AE, Languino L, Fatatis A, Rui H, Nevalainen MT.

Am J Pathol. 2015 Sep;185(9):2505-22. doi: 10.1016/j.ajpath.2015.04.026.

23.

The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.

Vido MJ, Aplin AE.

J Invest Dermatol. 2015 Oct;135(10):2355-2357. doi: 10.1038/jid.2015.239.

24.

Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma.

Capparelli C, Rosenbaum S, Berger AC, Aplin AE.

J Biol Chem. 2015 Oct 2;290(40):24267-77. doi: 10.1074/jbc.M115.657270. Epub 2015 Aug 12.

25.

ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.

Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE.

Cancer Res. 2015 Sep 1;75(17):3554-67. doi: 10.1158/0008-5472.CAN-14-2959. Epub 2015 Jul 23.

26.

PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma.

Kubic JD, Lui JW, Little EC, Ludvik AE, Konda S, Salgia R, Aplin AE, Lang D.

J Biol Chem. 2015 Sep 4;290(36):21901-14. doi: 10.1074/jbc.M115.670976. Epub 2015 Jul 23.

27.

RAC1 P29S regulates PD-L1 expression in melanoma.

Vu HL, Rosenbaum S, Purwin TJ, Davies MA, Aplin AE.

Pigment Cell Melanoma Res. 2015 Sep;28(5):590-8. doi: 10.1111/pcmr.12392.

28.

Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma.

Cheng H, Terai M, Kageyama K, Ozaki S, McCue PA, Sato T, Aplin AE.

Cancer Res. 2015 Jul 1;75(13):2737-48. doi: 10.1158/0008-5472.CAN-15-0370. Epub 2015 May 7.

29.

NF-κB Regulation of c-FLIP Promotes TNFα-Mediated RAF Inhibitor Resistance in Melanoma.

Shao Y, Le K, Cheng H, Aplin AE.

J Invest Dermatol. 2015 Jul;135(7):1839-1848. doi: 10.1038/jid.2015.91. Epub 2015 Mar 9.

30.

Game of isoforms: PI3K β-sparing inhibitor is coming.

Cheng H, Aplin AE.

Pigment Cell Melanoma Res. 2015 Mar;28(2):133-4. doi: 10.1111/pcmr.12350. Epub 2015 Jan 30. No abstract available.

PMID:
25573297
31.

FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma.

Weiss MB, Abel EV, Dadpey N, Aplin AE.

Mol Cancer Res. 2014 Sep;12(9):1314-23. doi: 10.1158/1541-7786.MCR-14-0170. Epub 2014 Jul 24.

32.

Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

Kugel CH 3rd, Hartsough EJ, Davies MA, Setiady YY, Aplin AE.

Cancer Res. 2014 Aug 1;74(15):4122-32. doi: 10.1158/0008-5472.CAN-14-0464. Epub 2014 Jul 17.

33.

Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.

Vu HL, Aplin AE.

Mol Cancer Res. 2014 Oct;12(10):1509-19. doi: 10.1158/1541-7786.MCR-14-0204. Epub 2014 Jun 24.

34.

Adaptive resistance to RAF inhibitors in melanoma.

Kugel CH 3rd, Aplin AE.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1032-8. doi: 10.1111/pcmr.12264. Epub 2014 Jun 6. Review.

35.

Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma.

Hartsough EJ, Basile KJ, Aplin AE.

Mol Cancer Res. 2014 May;12(5):795-802. doi: 10.1158/1541-7786.MCR-13-0581. Epub 2014 Feb 11.

36.

Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.

Basile KJ, Le K, Hartsough EJ, Aplin AE.

Pigment Cell Melanoma Res. 2014 May;27(3):479-84. doi: 10.1111/pcmr.12218. Epub 2014 Feb 10.

37.

Hippo: hungry, hungry for melanoma invasion.

Sanchez IM, Aplin AE.

J Invest Dermatol. 2014 Jan;134(1):14-16. doi: 10.1038/jid.2013.372. Erratum in: J Invest Dermatol. 2014 Jun;134(6):1779.

38.

In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors.

Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, Aplin AE.

Cancer Res. 2013 Dec 1;73(23):7101-10. doi: 10.1158/0008-5472.CAN-13-1628. Epub 2013 Oct 11.

39.

Resistance to RAF inhibitors revisited.

Hartsough E, Shao Y, Aplin AE.

J Invest Dermatol. 2014 Feb;134(2):319-325. doi: 10.1038/jid.2013.358. Epub 2013 Oct 10. Review.

40.

A STATement on vemurafenib-resistant melanoma.

Hartsough EJ, Aplin AE.

J Invest Dermatol. 2013 Aug;133(8):1928-9. doi: 10.1038/jid.2013.136.

41.

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.

Abel EV, Basile KJ, Kugel CH 3rd, Witkiewicz AK, Le K, Amaravadi RK, Karakousis GC, Xu X, Xu W, Schuchter LM, Lee JB, Ertel A, Fortina P, Aplin AE.

J Clin Invest. 2013 May;123(5):2155-68. doi: 10.1172/JCI65780. Epub 2013 Apr 1.

42.

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.

Le K, Blomain ES, Rodeck U, Aplin AE.

Pigment Cell Melanoma Res. 2013 Jul;26(4):509-17. doi: 10.1111/pcmr.12092. Epub 2013 Apr 8.

43.
44.

TWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cells.

Weiss MB, Abel EV, Mayberry MM, Basile KJ, Berger AC, Aplin AE.

Cancer Res. 2012 Dec 15;72(24):6382-92. doi: 10.1158/0008-5472.CAN-12-1033. Epub 2012 Dec 7.

45.

SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.

Kaplan FM, Kugel CH 3rd, Dadpey N, Shao Y, Abel EV, Aplin AE.

J Biol Chem. 2012 Dec 7;287(50):41797-807. doi: 10.1074/jbc.M112.390906. Epub 2012 Oct 17.

46.

Resistance to chemotherapy: short-term drug tolerance and stem cell-like subpopulations.

Basile KJ, Aplin AE.

Adv Pharmacol. 2012;65:315-34. doi: 10.1016/B978-0-12-397927-8.00010-5. Review.

PMID:
22959030
47.

BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.

Shao Y, Aplin AE.

Cell Death Differ. 2012 Dec;19(12):2029-39. doi: 10.1038/cdd.2012.94. Epub 2012 Aug 3.

48.

The Yin-Yang of RAF inhibitors.

Vu HL, Aplin AE.

Pigment Cell Melanoma Res. 2012 Mar;25(2):127-8. doi: 10.1111/j.1755-148X.2011.00947.x. Epub 2012 Jan 19. No abstract available.

PMID:
22409366
49.

ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity.

Shao Y, Aplin AE.

Cell Death Dis. 2012 Jan 19;3:e253. doi: 10.1038/cddis.2011.137.

50.

Meeting report from the 2011 International Melanoma Congress, Tampa, Florida.

Smalley KS, Aplin AE, Flaherty KT, Hoeller C, Bosserhoff AK, Haass NK, Bosenberg M, Ribas A, Barnhill R, Kudchadkar R, Messina JL.

Pigment Cell Melanoma Res. 2012 Jan;25(1):E1-11. doi: 10.1111/j.1755-148X.2011.00943.x. Epub 2011 Dec 9. No abstract available.

PMID:
22117673

Supplemental Content

Loading ...
Support Center